GlassScriptPhysician profile
Stanton A Welsh
NPI 1215587266
$5,260.53
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,083 · 2022: $2,102 · 2023: $1,960 · 2024: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $882.35 | 2021-2024 | |
| Alkermes, INC. | $643.58 | 2021-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $560.33 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $552.78 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $539.70 | 2021-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $517.32 | 2021-2023 | |
| Indivior INC. | $472.46 | 2021-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $363.30 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $277.48 | 2021-2023 | Rexulti |
| Lundbeck LLC | $109.71 | 2021-2023 | Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $86.43 | 2021-2023 | Trintellix |
| Almatica Pharma LLC | $65.83 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $48.41 | 2021-2022 | |
| Corium, LLC | $31.84 | 2023 | Azstarys |
| Owp Pharmaceuticals, INC. | $24.25 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.94 | 2023 | Sunosi |
| Idorsia Pharmaceuticals US INC | $21.63 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $21.63 | 2023 | Nuplazid |
| Tris Pharma INC | $19.56 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanton Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.